Catalent price target raised to $82 from $58 at Barclays

Barclays analyst Luke Sergott raised the firm’s price target on Catalent to $82 from $58 and keeps an Overweight rating on the shares. The analyst says the modest cut to the company’s underlying guidance "gave investors partially what they were looking for." The new guidance implies a significant Q3 to Q4 ramp that partially depends on major gene therapy project ramping, the analyst tells investors in a research note.